Cell and Gene Therapies

Translational Impact

We focus on transforming advances in cell and gene therapies into next-generation therapeutics. In close collaboration with scientists and clinicians across Stanford University and Stanford Medicine, we integrate cutting-edge discovery research with robust translational platforms to develop innovative cell and gene therapies for patients with unmet medical needs.

Cell & Gene Therapies at the IMA

The Innovative Medicines Accelerator (IMA) Cell & Gene Therapies Group is dedicated to advancing next-generation genetic interventions. We work at the interface of stem cell biology, immunology, and translational medicine to design therapies that precisely correct, replace, or reprogram disease-driving mechanisms. Our expertise spans gene editing, AAV vector engineering and manufacturing and engineered immune cell therapies. We develop both in vivo and ex vivo strategies, integrating cutting-edge genome editing technologies with optimized viral and non-viral delivery platforms. A core strength of the group is our capability in AAV manufacturing and process development, enabling scalable, high-quality vector production to support preclinical studies and early clinical translation. By combining vector design and robust production workflows, we accelerate the path from discovery to therapeutic candidate.